BL-M11D1

BL-M11D1 is SystImmune's CD33-directed antibody-drug conjugate (ADC) built on the gemtuzumab antibody backbone, armed with a novel topoisomerase I inhibitor payload (Ed-04) at drug-to-antibody ratio 10, joined by a cathepsin B cleavable linker. It is in Phase 1 for relapsed/refractory acute myeloid leukemia (AML). Only one CD33 ADC has ever reached the market (Pfizer's Mylotarg), and every serious follow-on has stumbled on liver toxicity. The commercial question is whether swapping the payload class and stabilizing the linker buys enough safety margin to matter. First-in-human data at ASH 2024 (39 patients, doses 0.6 to 2.75 mg/kg) reported no veno-occlusive disease, no dose-limiting toxicities, and encouraging activity in refractory patients [11], which is the single most important early signal for this class.

Investigational, never approved anywhere. FDA cleared the US IND in October 2024 [12], and Yale is a listed US site alongside Chinese centers, giving BL-M11D1 a genuine dual-jurisdiction development pathway rather than a China-only program. Two SystImmune/Sichuan Baili trials are recruiting: NCT05924750, a Phase 1 dose-escalation in relapsed/refractory AML targeting 130 patients [1], and NCT07255872, a Phase 2 combining BL-M11D1 with either 7+3 induction (cytarabine plus daunorubicin) or the current standard for unfit patients (venetoclax plus azacitidine), targeting 216 patients [2]. A related Phase 1 in relapsed/refractory MDS (NCT07591168) opened in 2025. No FDA breakthrough, fast-track, orphan, or accelerated-approval designations have been disclosed. SystImmune is privately held and does not file publicly with the SEC. BL-M11D1 sits outside the Bristol Myers Squibb partnership that covers BL-B01D1 (SystImmune's EGFR/HER3 bispecific ADC, licensed to BMS on December 11, 2023 for $800M upfront, up to $500M in near-term contingent payments, and up to $7.1B in development, regulatory, and sales milestones for a headline total of $8.4B, with BMS taking ex-China rights and SystImmune retaining mainland China) [3]. Any commercial narrative for BL-M11D1 therefore depends on SystImmune's own capital and a possible future ex-China partnering event. First-in-human dose-escalation data was presented at ASH 2024 [11]. No BL-M11D1 update was highlighted in the ALAN ASH 2025 AML recap, suggesting either a lower-visibility venue update or a decision to wait for more mature data. The next high-visibility readout window is ASH 2026 (December 2026).

CD33 is a receptor that sits on the surface of cells in the myeloid lineage, a family of white blood cells and their bone-marrow precursors. It shows up on the blast cells (leukemia cells) of roughly 85 to 90% of acute myeloid leukemia patients, which is why it has been an ADC target for two decades [4]. An antibody-drug conjugate is a targeted delivery system: an antibody that recognizes CD33 is chemically tethered to a cytotoxic drug, so the poison rides the antibody to the leukemia cell and gets internalized before it is released. BL-M11D1 uses gemtuzumab (the same anti-CD33 antibody that Pfizer's Mylotarg uses) linked via a stable cathepsin B cleavable linker to a novel topoisomerase I inhibitor payload (Ed-04) at a drug-to-antibody ratio of 10 [13]. The topo I payload class is the same chemistry that powers trastuzumab deruxtecan (Enhertu), the ADC that redrew HER2 breast cancer [5]. This is a different mechanism from Mylotarg, which uses calicheamicin (a DNA double-strand breaker) tethered via an acid-labile hydrazone linker whose instability contributed to premature payload release and the well-known hepatotoxicity profile [6]. Two things separate BL-M11D1 from prior CD33 ADC failures: the payload class (topo I inhibitor rather than calicheamicin or PBD-dimer) and the linker (cathepsin B cleavable rather than acid-labile hydrazone as in Mylotarg or protease-cleavable PBD as in vadastuximab). DAR=10 is high for an ADC and puts BL-M11D1 in the same loading range as T-DXd (DAR ~8). CD33 as a target is validated: Mylotarg improved event-free survival when added to standard induction chemotherapy in favorable-risk AML. The open question is whether a topo I payload at high DAR with a stable enzyme-cleavable linker delivers a wider therapeutic window than the prior two payload generations.

The lead trial, NCT05924750, is a standard Phase 1a/1b dose-escalation and expansion in relapsed/refractory AML, sponsored by Sichuan Baili, n=130, primary endpoint dose-limiting toxicity [1]. Dose escalation in AML is unforgiving: the disease progresses fast, so slow escalation costs patients, and cytopenias make it hard to distinguish drug toxicity from disease effect. There is no comparator arm, which is standard for Phase 1 but means efficacy will be judged against historical response rates in r/r AML (roughly 15 to 25% complete remission for salvage regimens). The ASH 2024 readout covered 39 patients dosed from 0.6 to 2.75 mg/kg (median age 53.9, mix of primary refractory, refractory, and relapsed AML), reported no DLTs and no grade 3 or higher organ injury at cutoff, no observed VOD, and encouraging anti-cancer activity in the refractory population [11]. The Phase 2 companion trial NCT07255872 is more ambitious: a 216-patient study of BL-M11D1 combined with 7+3 induction chemotherapy in fit newly diagnosed AML patients, or with venetoclax plus azacitidine in unfit patients, primary endpoint objective response rate [2]. Layering an ADC on top of both current standards of care is aggressive. The risk is compounded myelosuppression, since AML induction is already at the ceiling of what marrow tolerates. Enrollment status for both trials is 'recruiting' as of the most recent registry entries. No interim analysis dates have been published.

Our model estimates a 15% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 21%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by a non-randomized design and its light or open-label blinding; it is held back by the sponsor's thin or weak approval record and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is a bystander-killing question. Topo I payloads require active DNA replication to exert cytotoxicity, consistent with AML's rapidly proliferating blast population, so the payload class fits the disease biology. The unresolved question is whether the bystander killing effect central to DXd-payload ADC success in solid tumors (killing antigen-negative neighbors via diffusion of released payload) operates meaningfully in AML, where tumor cells are dispersed in marrow and circulation rather than packed in a localized mass. Bystander killing may matter less when CD33-negative escape blasts are not spatially adjacent to CD33-positive targets. CD33 antigen density varies across AML subtypes, and low-expressing blasts can escape ADC therapy: this resistance mechanism is well-documented for Mylotarg [4]. Safety risk is dominated by hepatotoxicity and veno-occlusive disease, both mechanism-linked to CD33 ADCs regardless of payload chemistry (CD33 is expressed on hepatic Kupffer cells). Mylotarg was pulled from the US market in 2010 for VOD before returning at a lower dose in 2017 [6]; vadastuximab talirine was killed by cumulative hepatotoxicity in the CASCADE trial the same year [8]. The Ed-04 topo I payload plus stable cathepsin B linker is the specific engineering thesis that BL-M11D1 has to prove buys real safety margin: the ASH 2024 no-VOD readout matters because it is the first proof point that a payload swap plus a stable enzyme-cleavable linker can break the class-linked liver-injury pattern. Off-target myelosuppression is guaranteed given CD33 expression on normal myeloid progenitors: the question is depth and recovery kinetics. Competitive risk beyond Mylotarg: the CD33 ADC field is thin post-vadastuximab, but CD33-directed bispecifics (Amgen's AMG 330 CD33xCD3 BiTE among them) have been in clinical development and represent adjacent competition. BL-M11D1 is currently the highest-profile second-generation CD33 ADC in active clinical development. Regulatory-path risk is meaningful. NCT05924750 is sponsored by Sichuan Baili, a Chinese company, and while the US IND clearance (October 2024) and Yale enrollment site enable a global development track, ex-China commercial value depends on SystImmune either funding expensive global registrational trials on its own capital or landing a BMS-like ex-China licensing deal. Precedent exists (BL-B01D1) but is not guaranteed. Execution risk is moderate. Sichuan Baili has run multiple ADC trials, and the BMS deal on BL-B01D1 shows the platform can produce compounds that pass major-pharma due diligence [3], but BL-M11D1 has no such external validation yet. Commercial risk if approved: venetoclax plus azacitidine has redefined unfit AML with median OS around 15 months [9], menin inhibitor revumenib is now approved for KMT2A-rearranged AML [10], and Mylotarg itself remains on the market. A CD33 ADC entering this space needs to beat those benchmarks, not match them.

Worth tracking, and the ASH 2024 signal has meaningfully improved the case. BL-M11D1 is a SystImmune/Sichuan Baili ADC with a real credential (the BMS deal on BL-B01D1 is a serious external vote of confidence in the underlying ADC chemistry [3]), and the first-in-human data delivered the single most important early readout for a CD33 ADC: no VOD, no DLTs at doses up to 2.75 mg/kg, and encouraging responses in refractory patients across 39 dosed subjects [11]. Every prior second-generation CD33 ADC has failed on liver toxicity, so clearing that bar in an early cohort is the specific signal that flips this asset from lottery ticket to credible platform bet. Efficacy detail (specific CR/CRi rates by dose level) was not extractable into secondary sources at the granularity needed for a confident conversion versus historical salvage benchmarks (roughly 15 to 25% CR for r/r AML), so the next data drop is where efficacy takes center stage. No BL-M11D1 update appeared in the ALAN ASH 2025 AML recap, which is either a mild negative signal (delayed maturity) or a scheduling artifact (data reserved for a later venue). The next high-visibility readout is ASH 2026 (December 2026), with Phase 1b expansion cohort data and, potentially, early Phase 2 combination signals. Market anchor: roughly 20,000 new AML diagnoses per year in the US and approximately 200,000 globally, with roughly half relapsing after first-line therapy, giving an r/r US population of about 10,000 patients per year at list prices of $100,000+ per course. This is a small but high-value indication where a differentiated CD33 ADC could plausibly do $500M+ annually in the US alone if it displaces Mylotarg in a specific line or defines a new salvage niche. The commercial path is almost certainly out-licensing: an ex-China deal structured like BL-B01D1 (substantial upfront, mainland China retained by SystImmune) is the realistic template. Data threshold to attract that deal: two consecutive readouts showing clean hepatic safety at biologically active doses plus CR/CRi rates in r/r AML above 25%. Until then, this is a science watch with an improving thesis, not yet a commercial position.